STOCK TITAN

Tandem Diabetes Stock Price, News & Analysis

TNDM Nasdaq

Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.

Tandem Diabetes Care (TNDM) delivers innovative insulin management solutions through advanced pump technology and connected diabetes care platforms. This news hub provides investors and healthcare professionals with timely updates on corporate developments, product milestones, and regulatory progress.

Access official press releases covering quarterly financial results, new product clearances, and strategic partnerships alongside analysis of market trends impacting diabetes care technology. Our curated collection ensures you stay informed about pump software updates, clinical trial outcomes, and international expansion efforts.

Key updates include FDA submissions, insulin delivery system enhancements, and operational developments across global markets. Bookmark this page for direct access to Tandem Diabetes' latest announcements, including pump compatibility improvements and user experience initiatives that shape modern diabetes management.

Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to release its first quarter 2021 results after market close on May 5, 2021. A conference call will follow at 4:30 PM ET to discuss the financial and operational results. Shareholders and interested parties can access details via dial-in numbers or through a live webcast. Tandem Diabetes is known for its innovative insulin delivery solutions, particularly the t:slim X2™ insulin pump that features remote software updates and integrated continuous glucose monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
-
Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced management will present a company update at two upcoming virtual investor conferences. The presentations are scheduled for the Barclays Global Healthcare Conference on March 10, 2021, at 3:00 PM ET and the Oppenheimer’s 31st Annual Healthcare Conference on March 17, 2021, at 2:30 PM ET. The updates will be webcast live, with an archive available for 30 days on Tandem's Investor Center website. This showcases Tandem's commitment to transparency and engagement with investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
conferences
-
Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has appointed Jordan Pinsker, MD, as Vice President and Medical Director, effective April 26, 2021. Dr. Pinsker, a renowned pediatric endocrinologist, previously led artificial pancreas research at Sansum Diabetes Research Institute, where he directed clinical trials for automated insulin delivery systems. His extensive experience in diabetes care and technology aligns with Tandem's mission to enhance insulin therapy management. The leadership addition aims to drive innovation in closed-loop insulin delivery and improve outcomes for individuals with diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
management
Rhea-AI Summary

Tandem Diabetes Care reported strong financial results for Q4 and FY 2020, with worldwide pump shipments increasing 67% to 32,685 and sales rising 55% to $168.1 million compared to Q4 2019. For the full year, sales reached $498.8 million, a 38% increase, while the gross profit improved 34% to $260.5 million. The company anticipates 20-23% sales growth for 2021, estimating revenue between $600 million and $615 million, with a gross margin of approximately 55%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
-
Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced upcoming presentations at various virtual investor conferences, highlighting its commitment to innovation in diabetes technology. Key events include the Citi 2021 Healthcare Services Conference on February 25, the SVB Leerink Global Healthcare Conference on February 26, the Raymond James 42nd Annual Institutional Investors Conference on March 1, and the Cowen 41st Annual Healthcare Conference on March 2. Live webcasts will be available, with recordings archived for 30 days on their Investor Center website.

For more information, visit investor.tandemdiabetes.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
conferences
-
Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to announce its fourth quarter and full year 2020 results on February 24, 2021. The announcement will be followed by a conference call at 4:30 PM ET to discuss financial and operational outcomes. Investors can access the live webcast and find an archived version for 30 days after the event. Tandem is known for its innovative t:slim X2 insulin pump, which features remote software updates and integrated continuous glucose monitoring, emphasizing its commitment to diabetes care improvement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced the appointment of Rajwant (Raj) Singh Sodhi as an independent board member effective January 1, 2021. He succeeds Edward Cahill, who has served since May 2009. Raj, president of the SaaS business at ResMed, brings over 25 years of digital strategy experience across healthcare, financial services, and telecom. Tandem's CEO, John Sheridan, highlighted Raj's expertise in software technologies as valuable for the company's growth and innovation in diabetes care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
management
-
Rhea-AI Summary

Tandem Diabetes Care (TNDM) reported strong Q3 2020 results with a 31% increase in sales to $123.6 million, up from $94.7 million in Q3 2019. Worldwide pump shipments rose 23% to 22,021 units. Domestic sales surged 36% to $107.5 million, while international sales saw a modest 2% increase. Although operating margin improved to negative 1%, a net loss of $9.4 million was recorded, higher than the previous year’s $2.9 million loss. The company updated its 2020 sales guidance to $465-$475 million, expecting 28%-31% annual growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
-
Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced upcoming presentations at three significant virtual investor conferences. The first will take place at the 29th Annual Credit Suisse Healthcare Conference on November 9, 2020, at 2:00 p.m. ET. The second event is the Stifel 2020 Healthcare Conference on November 17, 2020, at 4:40 p.m. ET. Lastly, the Nasdaq 43rd Investor Conference will occur on December 4, 2020, at 12:30 p.m. ET. Webcasts of these presentations will be available live and archived for 30 days on the company’s Investor Center website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences
Rhea-AI Summary

Tandem Diabetes Care (NASDAQ: TNDM) will announce its third quarter 2020 results on November 5, 2020, after market close. A conference call and webcast will be held at 4:30 PM ET to discuss the financial and operational results. This session can be accessed through a toll-free number or via a webcast link. An archive of the event will be available for 30 days on the company’s Investor Center website. Tandem is known for its innovative insulin delivery systems, notably the t:slim X2 insulin pump.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags

FAQ

What is the current stock price of Tandem Diabetes (TNDM)?

The current stock price of Tandem Diabetes (TNDM) is $21.32 as of May 6, 2025.

What is the market cap of Tandem Diabetes (TNDM)?

The market cap of Tandem Diabetes (TNDM) is approximately 1.2B.
Tandem Diabetes

Nasdaq:TNDM

TNDM Rankings

TNDM Stock Data

1.16B
66.01M
0.85%
110.82%
10.73%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
San Diego